{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:52:13Z","timestamp":1771336333612,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Oncology"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/s1470-2045(14)70444-9","type":"journal-article","created":{"date-parts":[[2014,9,28]],"date-time":"2014-09-28T09:36:48Z","timestamp":1411897008000},"page":"1351-1360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"title":["Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial"],"prefix":"10.1016","volume":"15","author":[{"given":"Joseph","family":"Gligorov","sequence":"first","affiliation":[]},{"given":"Dinesh","family":"Doval","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Bines","sequence":"additional","affiliation":[]},{"given":"Emilio","family":"Alba","sequence":"additional","affiliation":[]},{"given":"Paulo","family":"Cortes","sequence":"additional","affiliation":[]},{"given":"Jean-Yves","family":"Pierga","sequence":"additional","affiliation":[]},{"given":"Vineet","family":"Gupta","sequence":"additional","affiliation":[]},{"given":"R\u00f4mulo","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Stefanie","family":"Srock","sequence":"additional","affiliation":[]},{"given":"Sabine","family":"de Ducla","sequence":"additional","affiliation":[]},{"given":"Ulrich","family":"Freudensprung","sequence":"additional","affiliation":[]},{"given":"Giorgio","family":"Mustacchi","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S1470-2045(14)70444-9_bib1","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/S1470-2045(14)70444-9_bib2","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib3","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib4","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","article-title":"1st International consensus guidelines for advanced breast cancer (ABC 1)","volume":"21","author":"Cardoso","year":"2012","journal-title":"Breast"},{"key":"10.1016\/S1470-2045(14)70444-9_bib6","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2010.31.5374","article-title":"Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials","volume":"29","author":"Gennari","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib7","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1200\/JCO.2006.06.1812","article-title":"Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer","volume":"24","author":"Gennari","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib8","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-010-0860-9","article-title":"Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study","volume":"122","author":"Alba","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(14)70444-9_bib9","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2012.45.2490","article-title":"Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02","volume":"31","author":"Park","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nrclinonc.2013.87","article-title":"Chemotherapy: maintenance therapy in breast cancer\u2013many questions remain","volume":"10","author":"Mart\u00edn","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib11","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1200\/JCO.2008.20.4107","article-title":"Issues in using progression-free survival when evaluating oncology products","volume":"27","author":"Fleming","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"suppl 9","key":"10.1016\/S1470-2045(14)70444-9_bib13","doi-asserted-by":"crossref","first-page":"ix128","DOI":"10.1016\/S0923-7534(20)32918-5","article-title":"Bevacizumab-capecitabine (BEV-CAP) after initial 1st-line bevacizumab-docetaxel (BEV-DOC) in patients (pts) with HER2-negative metastatic breast cancer (mBC): safety analysis of the IMELDA trial","volume":"23","author":"Gligorov","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10549-011-1695-8","article-title":"Final overall survival results and effect of prolonged (\u2265 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial","volume":"130","author":"Smith","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S1470-2045(14)70444-9_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10549-011-1685-x","article-title":"First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study","volume":"129","author":"Aogi","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"suppl","key":"10.1016\/S1470-2045(14)70444-9_bib16","article-title":"Arobase: a phase III trial of exemestane (Exe) and bevacizumab (BEV) as maintenance therapy in patients (pts) with metastatic breast cancer (MBC) treated in first line with paclitaxel (P) and BEV\u2014a Gineco study","volume":"32","author":"Tr\u00e9dan","year":"2014","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib17","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib18","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1470-2045(14)70439-5","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib19","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1093\/annonc\/mdu098","article-title":"Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial","volume":"25","author":"Barlesi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib20","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/JCO.2012.43.7459","article-title":"Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea","volume":"31","author":"Gerber","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib21","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1200\/JCO.2010.33.9101","article-title":"Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer","volume":"29","author":"Stockler","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0025-5564(84)90061-0","article-title":"A mathematical model of the effects of drug resistance in cancer chemotherapy","volume":"72","author":"Birkhead","year":"1984","journal-title":"Math Biosci"},{"key":"10.1016\/S1470-2045(14)70444-9_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0025-5564(97)00080-1","article-title":"A mathematical model of drug resistance: heterogeneous tumors","volume":"147","author":"Panetta","year":"1998","journal-title":"Math Biosci"},{"key":"10.1016\/S1470-2045(14)70444-9_bib24","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1586\/era.12.85","article-title":"Breast cancer intratumor genetic heterogeneity: causes and implications","volume":"12","author":"Ng","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/S1470-2045(14)70444-9_bib25","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1200\/JCO.2002.20.6.1456","article-title":"Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel","volume":"20","author":"Smith","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/S1470-2045(14)70444-9_bib26","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1470-2045(12)70566-1","article-title":"Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial","volume":"14","author":"Lang","year":"2013","journal-title":"Lancet Oncol"},{"issue":"suppl 9","key":"10.1016\/S1470-2045(14)70444-9_bib27","doi-asserted-by":"crossref","first-page":"ixe9","DOI":"10.1016\/S0923-7534(20)34318-0","volume":"23","author":"Masi","year":"2012","journal-title":"Ann Oncol"}],"container-title":["The Lancet Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204514704449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470204514704449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:11:24Z","timestamp":1761459084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470204514704449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["S1470204514704449"],"URL":"https:\/\/doi.org\/10.1016\/s1470-2045(14)70444-9","relation":{},"ISSN":["1470-2045"],"issn-type":[{"value":"1470-2045","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial","name":"articletitle","label":"Article Title"},{"value":"The Lancet Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S1470-2045(14)70444-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}